Elixiron Immunotherapeutics Announces Closing of $27 Million Series A-1 Financing Round to Progress Alzheimer’s Disease and Vitiligo Clinical-Stage Assets
Elixiron Immunotherapeutics, Inc., a privately held company developing therapeutics for cancer, neurological diseases and inflammatory disorders, has announced the closing of a Series A-1 extension financing round, bringing the total Series A-1 raise to $27 million. Proceeds will be used to advance phase 1 trials of two pipeline candidates and take three immuno-oncology assets towards IND applications. EI-1071 is an orally available, highly potent Colony-Stimulating Factor 1 Receptor inhibitor that is in a phase 1 trial in part thanks to an Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program award, with the goal of progressing EI-1071 into an Alzheimer’s disease trial. EI-001 is a fully human antibody that neutralizes an immuno-modulatory target of interest in Vitiligo and some other immunological disorders including Chronic Hepatitis B.
Elixiron was founded in 2017 and is led by Hung-Kai Chen, Founder, CEO and Chairman of the Board. The executive team includes Pandelakis Koni, Executive Vice President of R&D, formerly Director of Research at the Parker Institute for Cancer Immunotherapy, and Carrie Duan, Executive Vice President of Clinical Development, who previously had leading roles in clinical development and medical affairs management with AstraZeneca, Bayer, GSK and other multinational companies.
“Elixiron firmly believes in drug innovation based on clinical findings from patients in need of better therapies,” said Hung-Kai Chen. Hung-Kai continued, “We use translational medicine to dig deep into the key mechanisms of treatment, from which we propose new strategies to modulate the immune system. This is combined with our innovative technology including the T-action platform that can greatly increase the activity of T cells in tumors, and with our new target discovery efforts using our B cell cloning and other antibody library platforms.”
The financing raise was jointly led by Pangu Capital (a new investor) and Taiwania Capital (an existing investor) and was joined by further new investors, including DCI Partners of Daiwa Securities Group, Mega International Commercial Bank, Fubon Financial Holdings and Hong Tai Electric Industrial, as well as other existing investors such as China Development Capital Industrial Bank (CDIB) Capital Group.
People In This Post
Companies In This Post
- Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
- Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
- Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
- Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
- Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more